Clinician, nurse or prescriber

Start with these three chapters

Appraise the clinical evidence, separate laboratory changes from outcomes, then examine the relevant compounding framework.

1. Read a study as a complete record
2. Testing the person: understand the clinical question
3. 503A and 503B: understand the pathway before the product

Then use the reading path and books for more depth, and complete the learning worksheet to record what you found.

Know which product the evidence describes

A molecule name is a starting point, not a complete product description. Record the active ingredient, chemical form, formulation, route, manufacturer or compounder and the document date. Products using similar names may differ in ways that matter. A result for one preparation does not automatically establish the performance of another.

FDA approval concerns a particular drug product and its authorized labeling. A facility registration, product listing or National Drug Code does not mean FDA has approved the product. A company can have legitimate paperwork for one activity without every product or claim being authorized.

Compounded drugs are prepared under a different framework and are not FDA-approved. They can serve particular patient needs, but FDA does not review each compounded product for safety, effectiveness and quality before marketing in the way it reviews approved medicines. The 503A and 503B pathways have different conditions, explained below.

Investigational means a product or use is being studied; it does not mean success is established. Research-use labeling concerns a claimed purpose and cannot establish suitability for human use. Keep regulatory status, analytical quality and clinical evidence as three separate entries. None can substitute for the other two.

Build a simple comparison: what the paper studied, what the official label describes, and what the current document or service names. Mark missing information rather than filling it with a brand assumption. This comparison is useful for a patient preparing questions and for a professional reviewing a brochure.

Read a study as a complete record

Begin with the primary paper and registry where available. A registry describes a planned or reported study; its presence does not prove benefit. Compare the registered population, outcomes and timing with the published account. Preserve publication date, study period and later update date as different facts.

Write the research question using population, intervention, comparator and outcome. Include species, formulation, route and duration. A comparison against placebo answers a different question from a comparison against an active medicine. A study in one population may leave other groups unrepresented.

Look at how participants entered the analysis. An estimate based on everyone assigned may differ from one describing participants who remained on treatment. Missing observations and treatment discontinuations can affect interpretation. Record the paper’s stated analysis and assumptions instead of merging estimates from different methods.

Check whether an outcome was primary, secondary or exploratory. Multiple measurements increase the opportunity for chance findings; the analysis plan and adjustments matter. A confidence interval describes uncertainty under the analysis assumptions. Statistical significance does not by itself establish a meaningful improvement in daily life.

Read withdrawals, adverse events and serious events alongside benefits. Retain reported causality assessments and comparator counts. Distinguish no event observed from evidence that an event cannot occur. Small studies and short follow-up may have limited ability to characterize uncommon or delayed harms.

Finally, separate the result from its interpretation. Note sponsor involvement, available methods and missing details. A sponsor release can report a development before full results are public; attribute it clearly and leave unresolved methods visible until the paper or registry supplies them.

Testing the person: understand the clinical question

A diagnostic laboratory studies specimens from a person to help assess health or investigate a clinical question. An analytical product laboratory studies material submitted for testing. These are different jobs. A blood report does not identify the contents of a product, and a product COA does not explain a patient’s symptoms or establish whether a treatment is appropriate.

Begin with the question the test is intended to answer. A test directory can explain the specimen required, the measurement method, its intended use, limitations and reporting details. Some tests are useful for one purpose but not another. Ordering recommendations are context-dependent. A list of tests mentioned online is not automatically a useful panel for every person, and this educational guide does not prescribe a monitoring schedule.

When reading a result, keep the patient and specimen identifiers, collection date, units, method and laboratory reference interval together. Reference intervals describe a comparison range used by that laboratory; they are not universal performance targets. Clinical decision thresholds may serve a different purpose from a reference interval. A result needs interpretation alongside symptoms, medical history and other findings, rather than being converted into a diagnosis from one isolated number.

Preparation, collection, transport and specimen condition can affect whether a result is interpretable. A laboratory’s directory may specify handling requirements, specimen stability and reasons for rejecting a sample. Those details belong to the particular test and method. Do not transfer storage information for a blood specimen to a medication, or treat one laboratory’s instructions as universal.

A change over time can raise a useful question without proving its cause. Differences in timing, clinical circumstances or analytical methods may matter. A normal result does not establish that an unapproved product is safe, and an abnormal result does not by itself establish that a product caused harm. The clinician and laboratory can help investigate unexpected or discordant results using the full clinical context.

In the United States, CLIA concerns laboratories testing human specimens for health assessment or diagnosis, prevention or treatment. CMS provides a public lookup for laboratory certification and demographics. Verify the particular performing facility and its certificate rather than assuming all sites within a company are equivalent. CLIA certification is not FDA approval of a peptide product, and it does not transform a product-purity report into a diagnostic test. Example laboratory directories are useful teaching resources, not endorsements or evidence that every listed service suits every person.

503A and 503B: understand the pathway before the product

Compounding means preparing a medicine for particular needs by combining, mixing or altering ingredients. In the United States, sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act establish different conditions for exemptions from certain federal requirements. They are not product-approval programs. A compounded medicine does not become FDA-approved because a pharmacy holds a license or an outsourcing facility appears in a registration database.

Section 503A concerns compounding by a licensed pharmacist in a state-licensed pharmacy or federal facility, or by a licensed physician. Its prescription condition concerns an identified individual patient. Limited anticipatory compounding can occur under specified conditions before a prescription arrives, but that is not unrestricted authority to supply unassigned office stock. When all applicable conditions are met, the product can qualify for exemptions from premarket approval, adequate-directions labeling and federal current good manufacturing practice requirements. Other requirements still apply.

Section 503B concerns outsourcing facilities, where compounding occurs by or under the direct supervision of a licensed pharmacist. These facilities remain subject to current good manufacturing practice, often abbreviated CGMP. They may obtain individual prescriptions or supply healthcare providers with office stock: medicine held before a particular patient needs it. FDA conducts risk-based inspections, and reporting obligations apply. Registration is not a guarantee that every preparation, practice or transaction complies.

Bulk ingredients have separate eligibility gates. Under 503A, FDA describes an applicable USP/NF monograph route; when no applicable monograph exists, a component-of-an-approved-drug route; or, when neither applies, inclusion on the 503A bulks list. Under 503B, a substance generally needs inclusion on the clinical-need bulks list, or the resulting drug must be on the shortage list at compounding, distribution and dispensing. A monograph is a published quality standard, not approval of every preparation made from the ingredient.

A valid certificate of analysis and manufacture by an FDA-registered establishment are additional bulk-substance conditions, not substitutes for eligibility. Interim enforcement policies are also distinct from the statutory lists: nomination or Category 1 status is not final list inclusion. Other limits, including restrictions involving essentially copies of available medicines, still need attention. Review the specific product, pathway and date rather than assuming that a familiar ingredient or a national shortage headline answers everything.

503A status as of October 31, 2026: interim Categories 1, 2 and 3 are not the final 503A bulks list. Category 1 concerns adequately supported nominations under evaluation; Category 2 identifies significant safety concerns; Category 3 concerns inadequate nomination support. Removal from Category 2 does not itself establish eligibility. An advisory-committee recommendation is nonbinding advice, not list inclusion. Addition to the final list requires FDA rulemaking; other 503A conditions still apply. Read the category record, committee record and final rule separately rather than treating one as a substitute for another.

Status-note sources checked October 31, 2026; this is not a claim that every retained source was re-reviewed.

Explain a claim with its evidence attached

A reader receives a message from the complete presentation: headline, image, testimonial, spoken words and qualifications. Write down the actual impression before judging the evidence. A document titled “education” can still communicate a product benefit or sales claim.

Keep a claim ledger with the exact wording, intended audience, primary source and relevant limits. Record the population, product, outcome and date. Attach a decision: supported as written, needs narrowing, or unanswered. This makes review repeatable when a sentence moves from a website to a printed handout.

Use plain language without removing uncertainty. Explain an unfamiliar term when it first appears. Put a consequential limitation beside the claim it qualifies. A small disclaimer elsewhere cannot repair an unsupported headline. Separate community reports from controlled evidence and company statements from independently established findings.

Give each document a content owner, version and review date. Preserve sources and consequential limitations when adapting it for another audience. Keep a change record so later readers can identify which claim changed and why.

Changed claims about presentation checked against FTC guidance October 31, 2026.

Where to report a problem and how to check a pharmacy

FDA MedWatch accepts reports of adverse events and product-quality problems. Record the product name, manufacturer or compounder, lot if available, dates, what happened and relevant packaging or photographs; distinguish what you observed from what you suspect caused it. A report communicates a concern and does not itself prove causation.

Use FDA BeSafeRx to learn how to evaluate an online pharmacy, then follow FDA’s state-pharmacy directory to the relevant board’s license lookup. Match the legal name and address, check the current license record and contact the board when an entry is unclear. A license lookup and a product-approval record answer different questions.

Sources for this addition checked October 31, 2026.

Reading path and books

Continue in the Church Library

Choose the depth that fits your background. Library entries include reading options and affiliate disclosures where applicable.

Browse all Library rooms →

Examples in practice

These examples identify published resources and their uses; they are not evaluated services.

Questions and explanations

Glossary

Comparator

The reference group or intervention against which an outcome is compared, such as placebo or another treatment.

Endpoint

An outcome defined for a study. A biological measurement and a patient-important outcome are not necessarily the same thing.

Formulation

The composition and presentation of a product, including ingredients beyond the active substance.

Adverse event

An unwanted medical occurrence during observation; occurrence does not itself establish a causal connection to treatment.

Investigational

Under investigation. This describes research status, not proof of safety or benefit.

API

Active pharmaceutical ingredient: the substance intended to provide a medicine’s pharmacological activity. An API is not the same as a finished medicine.

503A / 503B

Different U.S. statutory pathways for qualifying compounded drugs. Neither makes a compounded drug FDA-approved.

CGMP

Current good manufacturing practice: requirements for manufacturing controls and quality. The applicable framework depends on the activity and product.

CLIA

Clinical Laboratory Improvement Amendments: a U.S. framework for laboratories testing human specimens for specified health purposes.

Reference interval

A laboratory’s comparison range for a test in a defined reference population. It is not a diagnosis on its own.

Confidence interval

A range expressing statistical uncertainty under an analysis’s assumptions; it does not remove bias or establish applicability.